Cargando…

Genetic screening for neovascular AMD: cost effective…not so quick

The following is a response to Brown and colleagues (Int J Retin Vitr 1:19, 2015), who analyzed the cost effectiveness of genetic screening for neovascular AMD in Category 3 (intermediate). As explained in this letter, it is premature to propose that genetic screening is cost effective in this setti...

Descripción completa

Detalles Bibliográficos
Autor principal: Reichel, Elias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088460/
https://www.ncbi.nlm.nih.gov/pubmed/27847617
http://dx.doi.org/10.1186/s40942-015-0024-5